STOCK TITAN
  1. Home
  2. News
  3. WINT

Windtree Therapeutics Inc - WINT STOCK NEWS

Welcome to our dedicated news page for Windtree Therapeutics (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Windtree Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Windtree Therapeutics's position in the market.

News
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
Rhea-AI Summary
Windtree Therapeutics plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3. Completed $12.4 million public offering. Cash and cash equivalents as of June 30, 2023, were $11.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
earnings
-
News
Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none
-
News
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
Rhea-AI Summary
Windtree Therapeutics, Inc. is a biotechnology company focusing on treating late-stage acute cardiovascular disorders. They are working on a first-in-class drug candidate, Istaroxime, for the critical emergency condition of cardiogenic shock. The drug has shown positive results in phase 2 trials and has the potential for fast development and regulatory approval. Windtree has milestones and news flow planned for the coming quarters. They could partner with another pharmaceutical company or commercialize the drug themselves. Big biopharma companies may also be interested in acquiring Windtree. The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a CAGR of 5.62% from 2023 to 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
none
News
Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.63%
Tags
conferences
-
News
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
Rhea-AI Summary
Windtree Therapeutics, Inc. reported financial results for Q1 2023, including a 58% reduction in average monthly cash burn compared to Q1 2022. The company raised $12.4 million in an underwritten public offering and received a Bid Price Compliance Letter from Nasdaq. They also announced patent coverage for their dual mechanism SERCA2a activator class of drug candidates. The company reported a net loss of $4.1 million for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.7%
Tags
earnings
-
News
Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.98%
Tags
none
News
Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.26%
Tags
offering
Stock WINT logo
Windtree Therapeutics Inc

Nasdaq:WINT

WINT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

WINT Stock Data

3.99M
4.55M
4.65%
12.91%
0.43%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Warrington

About WINT

windtree therapeutics, inc. is a biotechnology company focused on developing novel kl4 surfactant therapies for respiratory diseases and other potential applications. windtree’s proprietary technology platform includes a synthetic, peptide-containing surfactant (kl4 surfactant ) that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized kl4 surfactant. windtree is focused initially on improving the management of respiratory distress syndrome (rds) in premature infants as surfactant therapy has been shown to save lives in this condition. windtree believes that its proprietary technologies may make it possible, over time, to develop a pipeline of kl4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies and, in doing so, potentially deliver a lifetime of hope to patients and their families.